Recombinant Rat MMP9 protein (His Tag)

ED50

/

Species

Rat

Purity

>90 %, SDS-PAGE

GeneID

81687

Accession

EDL96479.1

Cat No : Eg0439

Print datasheet

Synonyms

Mmp9,matrix metallopeptidase 9



Technical Specifications

Purity >90 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Not tested
Source HEK293-derived Rat MMP9 protein Ala20-Pro708 (Accession# EDL96479.1) with a His tag at the C-terminus.
Predicted Molecular Mass 80.2 kDa
SDS-PAGE 75-100 kDa, reducing (R) condition
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

MMP9 (matrix metallopeptidase 9), also named as Gelatinase B, is a member of matrix metalloproteinase (MMP) family. The MMP family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in normal embryogenesis, tissue remodelling and many diseases such as arthritis, cancer, periodontitis, glomerulonephritis, encephalomyelitis, atherosclerosis and tissue ulceration. MMP9 is produced by a variety of normal and transformed cells including neutrophils, monocytes, macrophages, astrocytes, fbroblasts, osteoclasts and so on. Transgenic mouse models report that MMP9 contributes to skin carcinogenesis, suppresses development of experimental abdominal aortic aneurysms, and triggers the angiogenic switch during carcinogenesis.

References:

1. Roy, Roopali et al. (2009) J Clin Oncol. 27(31):5287-5297. 2. Tanindi, Asli et al. (2011) Open Cardiovasc Med J. 5:110-116. 3. Coussens, L M et al. (2000) Cell. 103(3):481-490. 4. Pyo, R et al. (2000) J Clin Invest. 105(11):1641-1649. 5.Bergers, G et al. (2000) Nat Cell Biol. 2(10):737-744.